Related Experiment Video
Updated: May 22, 2025
04:49
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
55
[Emerging therapies for inflammatory rheumatic diseases].
Florence Fourel1, Diana Dan1, Alexandre Dumusc1
1Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|March 13, 2025
Summary
Managing inflammatory rheumatic diseases like rheumatoid arthritis is challenging. New treatments and monitoring strategies are needed as remission remains elusive for many patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Context:
- Inflammatory rheumatic diseases, including rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis, present ongoing management challenges for rheumatologists.
- Despite therapeutic advancements, achieving disease remission is not consistently possible for all patients.
- There is a continuous need for novel therapeutic strategies in rheumatology.
Purpose:
- To review recent advancements in the management of inflammatory rheumatic diseases.
- To highlight new drugs, therapeutic classes, and innovative applications of existing treatments.
- To discuss the importance of residual level monitoring in optimizing patient outcomes.
Summary:
- This review synthesizes findings from major European and American rheumatology congresses.
- It covers evaluations of current clinical practices and emerging therapeutic options.
- Focus areas include novel drug classes, repurposed medications, and therapeutic drug monitoring.
Impact:
- Provides clinicians with an updated overview of treatment strategies for inflammatory rheumatic diseases.
- Informs about the potential of new and existing therapies to improve patient remission rates.
- Emphasizes the evolving landscape of rheumatologic care and the pursuit of better patient outcomes.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
01:24T Cell Types and Functions
740
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
740